Home

Anne Prener

CIK 1797917 · last filed 2026-07-06

Anne Prener is a corporate insider who has filed 13 SEC Form 4 insider transactions across 4 companies since 2020. The most recent filing, for KROS, was dated Jul 6, 2026. Current disclosed insider exposure totals $138.8K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$138.8K

Companies

4

Total Filings

13

Lifetime Open-Market Net

$0

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KROS Director 13,786 $10.07 $138.8K $0 1 2026-07-06
Damora Therapeutics, Inc. (GLTO) Delisted Director — $28.69 — $0 6 2025-06-20
Rubius Therapeutics, Inc. (RUBY) Delisted Director — $0.08 — $0 3 2022-05-13
Kaleido Biosciences, Inc. (KLDO) Delisted Director — $0.29 — $0 3 2021-07-01

Recent Filings

13 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-06 KROS Grant (A) +13,786 $0 EDGAR
2025-06-20 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2024-06-21 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2023-06-15 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2022-06-15 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2022-05-13 Rubius Therapeutics, Inc. (RUBY) Delisted Grant (A) — $0 EDGAR
2021-07-01 Kaleido Biosciences, Inc. (KLDO) Delisted Grant (A) — $0 EDGAR
2021-05-28 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
2021-05-13 Rubius Therapeutics, Inc. (RUBY) Delisted Grant (A) — $0 EDGAR
2021-01-08 Damora Therapeutics, Inc. (GLTO) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 13
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.